Market Cap | 220.71M | P/E | - | EPS this Y | 33.10% | Ern Qtrly Grth | - |
Income | -66.71M | Forward P/E | -2.98 | EPS next Y | 20.20% | 50D Avg Chg | -17.00% |
Sales | 1.84M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 19.00% |
Dividend | N/A | Price/Book | 1.40 | EPS next 5Y | - | 52W High Chg | -32.00% |
Recommedations | 1.70 | Quick Ratio | 17.74 | Shares Outstanding | 48.26M | 52W Low Chg | 169.00% |
Insider Own | 6.08% | ROA | -27.41% | Shares Float | 13.87M | Beta | 0.49 |
Inst Own | 78.00% | ROE | -44.54% | Shares Shorted/Prior | 272.15K/313.60K | Price | 5.22 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 109,916 | Target Price | 4.00 |
Oper. Margin | -3,915.18% | Earnings Date | Nov 7 | Volume | 105,808 | Change | -2.06% |
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
HC Wainwright & Co. | Buy | Aug 12, 24 |
Wedbush | Neutral | May 29, 24 |
HC Wainwright & Co. | Buy | May 29, 24 |
Wedbush | Outperform | May 14, 24 |
HC Wainwright & Co. | Buy | Mar 19, 24 |
HC Wainwright & Co. | Buy | Mar 12, 24 |
Wedbush | Outperform | Jan 19, 24 |
HC Wainwright & Co. | Buy | Jan 19, 24 |
HC Wainwright & Co. | Buy | Nov 9, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC | Director Director | Jun 22 | Buy | 4.25 | 252,225 | 1,071,956 | 2,098,097 | 06/24/22 |
Bonita David P | Director Director | Jun 22 | Buy | 4.25 | 252,225 | 1,071,956 | 2,098,097 | 06/24/22 |
Zhang Xiaoyan Michelle | Chief Scientific Off.. Chief Scientific Officer | Jan 10 | Option | 2.15 | 1,000 | 2,150 | 45,439 | 01/12/22 |
Zhang Xiaoyan Michelle | Chief Scientific Off.. Chief Scientific Officer | Jan 10 | Sell | 12 | 1,000 | 12,000 | 44,475 | 01/12/22 |
Zhang Xiaoyan Michelle | Chief Scientific Off.. Chief Scientific Officer | Dec 10 | Option | 2.15 | 1,000 | 2,150 | 45,475 | 12/14/21 |
Zhang Xiaoyan Michelle | Chief Scientific Off.. Chief Scientific Officer | Dec 10 | Sell | 14.76 | 1,000 | 14,760 | 44,475 | 12/14/21 |
FORMELA JEAN FRANCOIS | Director Director | Mar 30 | Buy | 16 | 125,000 | 2,000,000 | 874,634 | 12/14/21 |
FORMELA JEAN FRANCOIS | Director Director | Mar 30 | Sell | 14.56 | 26,278 | 382,608 | 1,241,935 | 12/14/21 |
Atlas Venture Fund XI, L.P. | 10% Owner 10% Owner | Mar 30 | Buy | 16 | 125,000 | 2,000,000 | 874,634 | 12/14/21 |
Atlas Venture Fund XI, L.P. | 10% Owner 10% Owner | Mar 30 | Sell | 14.56 | 26,278 | 382,608 | 1,241,935 | 12/14/21 |